Screener
ANI Pharmaceuticals ANIP Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 60.4%-0.7pp | 60.8%+1.5pp | 61.4%+2.1pp | 61.1%+1.4pp | 61.1%-0.3pp | |
| Operating margin | 15.4%— | 13.4%— | 12.6%— | —— | —— | |
| Net margin | 11.1%+12.4pp | 10%+13.1pp | 8.9%+11.9pp | 4.9%+6.2pp | -1.4%-6.4pp | |
| Returns | ||||||
| Return on equity | 21%+23.2pp | 18.8%+23.6pp | 16.6%+21.0pp | 8.9%+10.6pp | -2.3%-8.5pp | |
| Return on invested capital | 21.3%+21.3pp | 17.2%+18.9pp | 15.7%+18.4pp | 7.9%+5.8pp | -0%-9.7pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×0.0× | 0.7×+0.1× | 0.6×+0.1× | 0.6×+0.1× | 0.7×+0.1× | |
| Liquidity | ||||||
| Current ratio | 2.9×+0.4× | 3.1×+0.5× | 2.7×0.0× | 2.6×-0.2× | 2.5×-1.4× | |
| Leverage | ||||||
| Debt-to-equity | 0.5×-0.2× | 0.5×-0.2× | 0.6×-0.2× | 0.6×-0.2× | 0.7×+0.1× | |
| Net debt / EBITDA | -0.2×-1.4× | -0×-2.5× | 0.2×-3.2× | 0.4×-2.1× | 1.1×+0.7× | |
| Per Share | ||||||
| Book value per share | $27.25+26.7% | $26.10+25.0% | $25.47+21.9% | $23.98+14.6% | $21.51-8.8% | |
| Valuation | ||||||
| Market capitalization | $1.88B+25.6% | $1.72B+18.3% | $1.77B+52.6% | $2.04B+62.7% | $1.45B+8.6% | |
| Price / earnings | 17.3×— | 18.7×— | 22.6×— | 50.3×— | —— | |
| Price / sales | 1.9×-0.1× | 1.9×-0.3× | 2×+0.1× | 2.5×+0.2× | 1.9×-0.5× | |
| Price / book | 3.1×-0.3× | 3.1×-0.4× | 3.3×+0.4× | 4×+0.9× | 3.3×+0.4× | |
| EV / EBITDA | 7.7×-11.2× | 8.1×-16.2× | 8.9×-16.4× | 14.2×-5.7× | 18.3×+5.8× | |
| Dividend yield | 0%-0.1pp | 0%-0.1pp | 0.1%-0.1pp | 0.1%-0.1pp | 0.1%0.0pp |
FAQ
- What are ANI Pharmaceuticals's profit margins?
- ANI Pharmaceuticals (ANIP) runs a 60.4% gross margin and a 15.4% operating margin, with a 11.1% net margin.
- Where do ANI Pharmaceuticals's ratios come from?
- Every ratio is computed from ANI Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
